cyc 202 has been researched along with gx 15-070 in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (gx 15-070) | Trials (gx 15-070) | Recent Studies (post-2010) (gx 15-070) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 175 | 15 | 133 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C | 1 |
1 other study(ies) available for cyc 202 and gx 15-070
| Article | Year |
|---|---|
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine | 2010 |